Page 118 - 2021_06-Haematologica-web

E. Haring et al.
et al. MHC class II antigen presentation by
the intestinal epithelium initiates graft-ver- sus-host disease and is influenced by the microbiota. Immunity. 2019;51(5):885-898 e887.
43. Sombetzki M, Fuchs CD, Fickert P, et al. 24- nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. J Hepatol. 2015;62(4):871-878.
44. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol. 2014;30(3):332-338.
45. Distrutti E, Santucci L, Cipriani S, et al. Bile
acid activated receptors are targets for reg- ulation of integrity of gastrointestinal mucosa. J Gastroenterol. 2015;50(7):707- 719.
46. Han S, Li T, Ellis E, Strom S, Chiang JY. A novel bile acid-activated vitamin D recep- tor signaling in human hepatocytes. Mol Endocrinol. 2010;24(6):1151-1164.
bile acid receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of GPBAR1 rescues mice from murine colitis. J Immunol. 2017;199(2):718-733.
49. Maruyama T, Miyamoto Y, Nakamura T, et al. Identification of membrane-type recep- tor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002;298(5):714-
47. Gadaleta RM, van Erpecum KJ, Oldenburg
B, et al. Farnesoid X receptor activation 719.
inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011;60(4):463-472.
48. Biagioli M, Carino A, Cipriani S, et al. The
50. Duboc H, Tache Y, Hofmann AF. The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig Liver Dis. 2014;46(4):302-312.
2146
haematologica | 2021; 106(8)